Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Recommendation of “Hold” by Analysts

Invivyd, Inc. (NASDAQ:IVVD) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $8.00.

IVVD has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Invivyd in a research report on Tuesday, June 9th.

Hedge Funds Weigh In On Invivyd

Hedge funds have recently bought and sold shares of the business. Courier Capital LLC acquired a new position in Invivyd during the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd during the fourth quarter worth $27,000. DRW Securities LLC acquired a new position in Invivyd during the fourth quarter worth $27,000. ProShare Advisors LLC acquired a new position in Invivyd during the fourth quarter worth $30,000. Finally, State of Wyoming acquired a new position in Invivyd during the fourth quarter worth $30,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Trading Down 5.2%

NASDAQ IVVD opened at $0.77 on Friday. Invivyd has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a market capitalization of $226.85 million, a PE ratio of -2.48 and a beta of 0.63. The firm’s fifty day simple moving average is $1.32 and its 200-day simple moving average is $1.77.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The company had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. As a group, analysts predict that Invivyd will post -0.5 EPS for the current year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.